Curaxis Pharmaceutical Corp.
Curaxis Pharmaceutical Corp.: CEO PATRICK S. SMITH COMMENTS ON RECENT NEW YORK TIMES ARTICLE
Curaxis Pharmaceutical Corp. / Key word(s): Miscellaneous
CURAXIS Pharmaceutical Corp. European Advisor: Andreea Porcelli ________________________________________________________________________ CURAXIS PHARMACEUTICAL CORP. CEO PATRICK S. SMITH COMMENTS ON RECENT NEW YORK TIMES ARTICLE ‘Mr. Wilson’s article mentions the recent failures of Alzheimer’s drugs in FDA trials sponsored by major pharmaceutical companies, which were largely based on beta amyloid that have shown no statistical significance in the trials, as well as having serious side effects on patients. Curaxis is taking a different approach to treating Alzheimer’s with a form of leuprolide proven to be extremely safe by reducing the overproduction of a leutenizing hormone that is commonly found in older people and scientific research has shown to be a contributing factor to Alzheimer’s,’ said Mr. Smith Curaxis’ lead hormone drug candidate Memryte has shown statistical results which appear equal to, if not better, than those reported of any Alzheimer’s drug in FDA trials according to some specialists in the field. Memryte, which targets the primary pathological events of Alzheimer’s disease, has also shown to stabilize Alzheimer’s in patients who have a moderate to advanced phase of the disease. Curaxis plans to enter Phase IIb trials to verify these findings and provide additional support that Memryte works to stabilize Alzheimer’s in combination with certain drugs known as acetylcholinesterase inhibitors (‘AChEIs’) of which Aricept is the most widely prescribed and going off patent this year. Curaxis has on file a patent pending for use of Memryte with AChEIs . ‘Our clinical work has shown a synergistic effect with Aricept and we believe the combination provides a better outcome when Memryte stops the aberrant cell cycling, allowing Aricept to work more effectively for a longer duration,’ added Mr. Smith. ‘We anticipate securing patents to provide a combination treatment at a very competitive price. Our findings are encouraging due to the safety of both drugs for many patient years.’ About Curaxis Notice Regarding Forward Looking Statements This press release includes certain ‘Forward-Looking Statements’ within the meaning of section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding potential results and future plans and objectives of Curaxis Pharmaceutical Corporation are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading ‘Risk Factors’ and elsewhere in our documents filed from time to time with the Securities and Exchange Commission. Other risk factors may include, but are not limited to, fluctuation in quarterly results, and increased competition in our operations, our ability to continue operations as scheduled, and our ability to protect the proprietary technology we use. Further, the company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the company’s control, such as announcements by competitors and service providers. # # # End of Corporate News 10.03.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
115071 10.03.2011 |